Amwell expects Q4 2026 revenue of $48M-$50M and adjusted EBITDA from breakeven to $1M (NYSE:AMWL)
Amwell (AMWL) expects Q4 2026 revenue of $48M-$50M and adjusted EBITDA from breakeven to $1M. CEO Ido Schoenberg highlighted progress toward profitability, aiming for positive cash flow and adjusted EBITDA for the year.
How this was made
The 30-second read
Why it matters
The key tradable input is the explicit Q4 2026 revenue range and adjusted EBITDA trajectory, which can drive expectation changes for future quarters and risk premium.
Market read
Forward guidance with specific revenue and adjusted EBITDA ranges can move AMWL’s valuation by updating the market’s profitability and growth expectations.
What to watch
Without details on cash burn, payer mix, utilization trends, or backlog, the guidance’s durability and path to sustained profitability remain uncertain.
Background
The article is an AI-generated earnings-call insights summary referencing AMWL’s execution toward profitability.
Ticker impact
American Well (AMWL) management is guiding Q4 2026 revenue to $48M-$50M and adjusted EBITDA from breakeven to $1M.
Likely upward bias if the market views the Q4 2026 revenue and EBITDA trajectory as credible versus expectations, otherwise downside if seen as conservative.
The headline contains explicit forward guidance numbers, which are typically market-moving for a loss-making healthcare services/software name; however, the provided body excerpt does not include consensus comparisons or additional context to gauge surprise magnitude.
Market effects
Reinforces the market’s focus on profitability milestones and cash-flow progress for telehealth/healthcare services providers.
No clear regional spillover indicated by the provided text.
Limited, as the disclosure is company-specific and US-listed.
Counterpoint
If investors interpret the guidance as achievable only with aggressive cost control or delayed demand recovery, the stock could still face skepticism despite EBITDA improvement.
Key entities
- companyAmerican Well Corporation
AMWL, telehealth/healthcare services provider issuing forward guidance for Q4 2026 revenue and adjusted EBITDA.



